F. Fornaroli

Wireless Capsule Endoscopy for Pediatric Small-Bowel Diseases

OBJECTIVE:Although capsule endoscopy (CE) is becoming an increasingly popular procedure, only recently data on its clinical application in pediatric gastroenterology are just emerging. Our aim is to investigate the diagnostic value of CE in small intestine diseases and to determine its safety, tolerance, and applicability in a large number of pediatric patients referred to our Tertiary Center of Pediatric Gastroenterology Unit, University of Parma.METHODS:A total of 87 Italian patients, 49 of which were male with an age range from 18 months to 18 yr with a suspected small-bowel disease (inflammatory bowel disease 37%, polyps 38%, obscure gastrointestinal bleeding 24%, malabsorption 1%), were investigated with the M2A capsule (GIVEN® Imaging Ltd., Yoqneam, Israel).RESULTS:A total of 77 patients swallowed the capsule, while in 10 it was endoscopically positioned (age range 1.5–11 yr, median age 5.3 yr). Eighty patients naturally evacuated the capsule, one patient needed surgery. The capsule evidenced pathological findings in 62 patients (71%), ileal lymphoid nodular hyperplasia in four subjects (5%), it was negative in 18 subjects (21%), and technically failed in three subjects (3%). In 21 out of 28 patients with known polyposis and in all the five patients with suspected polyposis, small-bowel polyps were found. In 16 out of 22 patients suffering from known inflammatory bowel disease (Crohns disease colitis or indeterminate colitis), small intestine lesions were found. CE examination identified a possible small intestine bleeding source in 13 out of 21 patients with suspected obscure gastrointestinal bleeding. In 5 out of 10 patients with suspected small-bowel inflammatory disease, CE evidenced ileum lesions suggesting Crohns disease, which was subsequently confirmed through diagnostic procedures and the clinical history. A patient with malabsorption presented a negative capsule study.CONCLUSIONS:Our experience, which includes the largest number of pediatric patients and the youngest child reported in literature, confirms that CE is a very useful system for the clinical work in suspected small-bowel diseases in infancy. The high rate of positive examination is due to the very careful selection of the patients, obligatory to conduct a safe examination since CE is not highly tested in children.

Short- and long-term efficacy of endoscopic balloon dilation in Crohn’s disease strictures

AIM To evaluate short- and long-term efficacy of endoscopic balloon dilation in a cohort of consecutive patients with symptomatic Crohns disease (CD)-related strictures. METHODS Twenty-six CD patients (11 men; median age 36.8 year, range 11-65 years) with 27 symptomatic strictures underwent endoscopic balloon dilation (EBD). Both naive and post-operative strictures, of any length and diameter, with or without associated fistula were included. After a clinical and radiological assessment, EBD was performed with a Microvasive Rigiflex through the scope balloon system. The procedure was considered successful if no symptom reoccurred in the following 6 mo. The long-term clinical outcome was to avoid surgery. RESULTS The mean follow-up time was 40.7 ± 5.7 mo (range 10-94 mo). In this period, forty-six EBD were performed with a technical success of 100%. No procedure-related complication was reported. Surgery was avoided in 92.6% of the patients during the entire follow-up. Two patients, both presenting ileocecal strictures associated with fistula, failed to respond to the treatment and underwent surgical strictures resection. Of the 24 patients who did not undergo surgery, 11 patients received 1 EBD, and 13 required further dilations over time for the treatment of relapsing strictures (7 patients underwent 2 dilations, 5 patients 3 dilations, and 1 patient 4 dilations). Overall, the EBD success rate after the first dilation was 81.5%. No difference was observed between the EBD success rate for naive (n = 12) and post-operative (n = 15) CD related strictures (P > 0.05). CONCLUSION EBD appears to be a safe and effective procedure in the therapeutic management of CD-related strictures of any origin and dimension in order to prevent surgery.

Usefulness of a serological panel test in the assessment of gastritis in symptomatic children.

Background: Non-invasive methods are advisable for the detection of Helicobacter pylori-related chronic gastritis in pediatric patients. Serum pepsinogens I and II (sPGII and sPGII), gastrin-17 (G-17) and anti-H. pylori antibodies (IgG-Hp) have been proposed as a ‘serological gastric biopsy’. Aim: To assess H. pylori infection and to evaluate gastric mucosa status in a pediatric population by means of serological parameters such as sPGI, sPGII, G-17 and IgG-Hp. Methods: 45 consecutively children evaluated for upper gastrointestinal symptoms were analyzed. All children were submitted to upper gastrointestinal endoscopy with biopsies. Serum samples were analyzed for IgG-Hp, sPGII, sPGI and G-17 (Biohit, Helsinki, Finland). Results: 18 children had H. pylori-related mild or moderate non-atrophic chronic gastritis. They presented significantly higher mean levels of sPGII and of IgG-Hp than negative ones, eitherunder or up to 10 years. sPGI showed significantly increased levels in H. pylori-positive patients only over 10 years. G-17 levels were not different between H. pylori-positive and -negative ones. The best cut-offs of IgG-Hp, sPGII and of product IgG-Hp·sPGII, to identify H. pylori infection, were 30 IU/l, 9 µg/l, and 241 IU/l·µg/l, respectively. The product IgG-Hp·sPGII identified H. pylori infection with a 100% sensitivity, 92% specificity, 90% positive predictive value and 100% negative predictive value. IgG-Hp and IgG-Hp showed a correlation (r = 0.94; p < 0.001). Conclusions: Combined analysis of sPGII and IgG-Hp antibody levels could be recommended as a non-invasive panel for the assessment of H. pylori-related histological alterations of gastric mucosa in childhood.

Primary Antimicrobial Susceptibility Changes in Children with Helicobacter pylori Infection over 13 Years in Northern Italy.

The eradication therapy of Helicobacter pylori (H. pylori) infection is still a challenge for gastroenterologists. One of the main causes of failure in H. pylori eradication is the antibiotic resistance mainly to clarithromycin. Culture from biopsies is maybe the most used method among the antimicrobial susceptibility techniques. In this study, we compared the antimicrobial susceptibility changes in children with H. pylori infection over 13 years and we confirmed that clarithromycin resistance has been increased (16% versus 26%) though with no statistically signficant value. Therefore, clarithromycin should not be used in empiric treatment of H. pylori eradication therapy in children, but its use should be limited only to children with known antimicrobial susceptibility. On the other hand, metronidazole resistance has decreased over this time period in statistically significant manner (56% versus 33%, p = 0.014). Furthermore, ampicillin resistance has been confirmed to be very rare (3% versus 0%) in children with H. pylori infection. In conclusion, in H. pylori infection, if we do not know the antibiotic susceptibility of patients, we should recommend an eradication therapy based on the local distribution of antibiotic resistance rates trying to limit the therapeutic failures.

A Role for Pathogenesis-Related Proteins in Poly-Sensitized Allergic Patients with Eosinophilic Esophagitis: Clinical and Endoscopic Features

Objective: Eosinophilic Esophagitis (EoE) is a chronic inflammatory disease of the esophagus often associated with atopy. Most EoE patients are poly-sensitized to inhalant and food allergens. Sensitization to pan-allergens is also frequent but their role in EoE is unclear. The aim of the study was to investigate the role of sensitization toward pathogenesis-related proteins (PR) in patients with EoE, and its relationship with clinical and endoscopic features. Methods: A group of poly-sensitized patients was retrospectively analyzed, and clinical, endoscopic, and histological differences were compared between patients’ sensitized and non-sensitized to PR-10 proteins. Results: Dysphagia was more frequent in patients sensitized to PR-10 compared with non-sensitized subjects (83% vs. 42%, p=0.032) while other presenting symptoms did not significantly differ between the two groups. The mean esophageal eosinophil peak was significantly higher in PR-10-sensitized patients (p=0.047). As far as endoscopic findings were concerned, no difference was found between the two groups. Conclusion: Sensitization to plant-food allergens such as PR-10 proteins seems relevant in poly-sensitized patients suffering from EoE and needs to be evaluated in order to test the result of an appropriate elimination diet.

Widespread Nivolumab-induced Enteropathy in a Long Responder Non–Small-cell Lung Cancer Patient

The outcomes of patients with advanced nonesmallcell lung cancer will be dramatically improved in a significant proportion of cases by administration of immune checkpoint blockers (ICBs) and further disruption of the programmed cell death 1 (PD-1)/ programmed cell death ligand 1 (PD-L1) axis. AntiePD-1 (nivolumab, pembrolizumab) and antiePDL1 (atezolizumab) agents have resulted in better and more durable disease responses compared with standard chemotherapy in the pretreatment setting. ICBs are generally well tolerated; nevertheless, immune-related toxicities can be severe and require special clinical attention given their potential to emerge at any time during or even after treatment. We report the case of a young woman with advanced lung adenocarcinoma who had continued to maintain a remarkable and sustained response to nivolumab for more than 2 years, which was administered as thirdline treatment. In our patient, nivolumab administration caused enteral toxicity several months after achieving a disease response. The enteral toxicity involved all portions of the upper and lower intestines at differential time points and led to definitive drug discontinuation. Considering the late-occurring, extensive involvement of the enteric tract by nivolumab immune-related toxicity, treatment with ICBs requires effective management.